Market News & Trends
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients With Heart Failure With Preserved Ejection Fraction
Imbria Pharmaceuticals, Inc. recently announced the enrollment of the first patient in Part 2 of the IMPROVE-DiCE Phase 2 clinical trial of ninerafaxstat in patients…
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
Derm-Biome Pharmaceuticals, Inc. recently announced that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego (UCSD)…
Centogene & Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Centogene N.V. recently announced it has extended the Rostock International Parkinson's Disease (ROPAD) Study to recruit and genetically test additional patients over the next few…
Celltrion & Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
Rani Therapeutics Holdings, Inc. recently announced it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar….
Transgene Receives Approval to Start a Phase 1 Trial of Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recently announced it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase 1 clinical trial of TG6050, a novel oncolytic….
Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy for the Treatment of Leber Congenital Amaurosis-2
Frontera Therapeutics recently announced it has dosed the first patient in a Phase 1 clinical trial of its lead gene therapy program, FT-001, for the…
Sarepta & Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Catalent, Inc. and Sarepta Therapeutics, Inc. recently announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced…
SAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-Idiotype Antibodies to Help Treat Autoimmune Diseases
SAB Biotherapeutics recently announced results from a project in collaboration with global biotechnology leader CSL confirming that SAB’s DiversitAb platform can generate functional fully human anti-idiotype polyclonal….
Paratek Pharmaceuticals Receives $36.4-Million Milestone Payment Associated With the Second Procurement of NUZYRA Under BARDA Project BioShield Contract
Paratek Pharmaceuticals, Inc. recently announced the receipt of a $36.4-million milestone payment associated with the second procurement of NUZYRA (omadacycline) under the company’s Project BioShield…
Ovid Therapeutics Dosed Healthy Volunteers With OV329 in Phase 1 Trial
Ovid Therapeutics Inc. recently dosed healthy volunteers with OV329 in late December 2022, as part of a Phase 1 study. The company is conducting the…
IMUNON Enters Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
IMUNON, Inc. and The Wistar Institute recently announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the….
Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Preclinical Trial
Clearmind Medicine Inc. recently announced positive preclinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at…
Purple Biotech & Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
Purple Biotech Ltd. recently announced a research collaboration with Mor Research Applications that provides Purple Biotech first access to early stage oncology product candidates owned by….
HRA Pharma Rare Diseases Registers the first Cushing’s Syndrome Treatment in Colombia
HRA Pharma Rare Diseases, an affiliate of HRA Pharma, a Perrigo Company, recently announced the registration of the first ever treatment for Cushing’s syndrome, Metopirone,…
Biognosys & Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma & Biomarker Customers
New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics….
Oncorus Announces Research Collaboration With Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise….
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Verrica Pharmaceuticals Inc. recently announced the successful completion of the technology transfer of bulk solution manufacturing to Piramal Pharma Solutions. The technology transfer includes the…
Certara Acquires Artificial Intelligence Company That Delivers Predictions to Accelerate Scientific Innovation
Certara, Inc. recently announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software that allows life sciences organizations to perform predictions and answer…
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for the Treatment of PCED
Kala Pharmaceuticals, Inc. recently announced the US FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human…
Gilead to Acquire All Remaining Rights to Potential First-In-Class Immunotherapy
Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under….
